Neuroone Medical Technologies
Neuroone Medical Technologies' revenue rose 163.5% to $9 million in fiscal 2025. Its operating margin was −46.5%, up from −344.3% a year earlier. Free cash flow was −$3 million. The diluted share count rose 50.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Neuroone Medical Technologies lost money in fiscal 2025: a net loss of $4 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 7 | 11 | — | 2 | 7 |
| Debt incl. finance leases | — | 0 | 0 | — | — |
| Net debt (negative means net cash) | — | −11 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.0x | 0.0x | — | — |
| Interest coverage | −3,346.9x | — | — | — | — |
| Current ratio | 6.2x | 3.9x | 4.1x | 2.1x | 4.4x |
| Quick ratio | 6.1x | 3.7x | 3.1x | 0.9x | 3.5x |
Cash flow
Projections
Project Neuroone Medical Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $736,999 of Neuroone Medical Technologies shares on the open market, and 1 insider sold $54,879.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | David J. WambekeChief Business Officer | Bought | 33,333 | $2.01 | $66,999 | Form 4 |
| Jun 30, 2026 | Mark ChristiansonMarket Development Director | Sold | 10,000 | $3.18 | $31,800 | Form 4 |
| Mar 30, 2026 | Mark ChristiansonBusiness Development Director | Sold | 15,363 | $0.74 | $11,369 | Form 4 |
| Mar 13, 2026 | Mark ChristiansonBusiness Development Director | Sold | 100 | $0.80 | $80 | Form 4 |
| Mar 12, 2026 | Mark ChristiansonBusiness Development Director | Sold | 817 | $0.80 | $654 | Form 4 |
| Mar 11, 2026 | Mark ChristiansonBusiness Development Director | Sold | 2,109 | $0.80 | $1,687 | Form 4 |
| Mar 10, 2026 | Mark ChristiansonBusiness Development Director | Sold | 11,611 | $0.80 | $9,289 | Form 4 |
| Mar 1, 2026 | David J. WambekeChief Business Officer | Bought | 1,000,000 | $0.67 | $670,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | — | — |
| Rule of 40 | 360.9% | −245.5% | 131.4% |
| Altman Z'' | −27.14 | −57.27 | −19.57 |
| Accruals ratio | 9.8% | −19.4% | −9.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | — | — |
Compare
Put Neuroone Medical Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Neuroone Medical Technologies | FY25 | 163.5% | −46.5% | −32.1% | — | — | — | |
| Milestone Scientific | FY25 | 4.0% | −63.5% | −32.7% | — | — | — | Compare |
| InspireMD | FY25 | 28.1% | −552.6% | −409.5% | — | — | — | Compare |
| Beyond Air | FY26 | 107.3% | −378.2% | −249.6% | — | — | — | Compare |
| Nexgel | FY25 | 31.5% | −29.4% | −12.1% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY15 | FY16 | FY17 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | — | — | — | 0 | 0 | 2 | 4 | 9 |
| Revenue growth | −100.0% | — | — | — | — | — | −3.9% | 1,040.7% | 76.9% | 163.5% |
| Gross profit | — | — | — | — | — | −0 | −0 | 0 | 1 | 5 |
| Research and development | — | — | 1 | 2 | 2 | 4 | 5 | 7 | 5 | 5 |
| Operating income | −0 | −0 | −3 | −6 | −5 | −10 | −10 | −12 | −12 | −4 |
| Net income | −0 | −0 | −5 | −7 | −14 | −10 | −10 | −12 | −12 | −4 |
| Diluted EPS (US$) | −0.03 | −0.03 | −2.31 | −1.71 | −2.52 | −0.93 | −0.63 | −0.65 | −0.46 | −0.09 |
| Diluted shares (millions) | 2 | 2 | 2 | 4 | 5 | 11 | 16 | 18 | 27 | 40 |
| Cash flow | ||||||||||
| Cash from operations | −0 | −0 | −2 | −5 | −3 | −9 | −8 | −13 | −11 | −3 |
| Capital expenditure | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | — | — | — | −5 | −4 | −9 | −8 | −13 | −11 | −3 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0 | 0 | 0 | 0 | 4 | 7 | 11 | — | 2 | 7 |
| Debt incl. finance leases | — | — | — | — | 1 | — | 0 | 0 | — | — |
| Total assets | 0 | 1 | 0 | 0 | 5 | 8 | 13 | 8 | 5 | 11 |
| Total liabilities | 0 | 1 | 5 | 2 | 3 | 1 | 3 | 2 | 4 | 4 |
| Shareholders' equity | −0 | −0 | −5 | −1 | 2 | 7 | 10 | 6 | 1 | 7 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | −54.9% | −41.4% | 23.4% | 31.3% | 56.5% |
| Operating margin | — | — | — | — | — | −5,735.9% | −5,860.1% | −612.3% | −344.3% | −46.5% |
| Net margin | — | — | — | — | — | −5,584.3% | −5,841.9% | −607.4% | −356.7% | −39.6% |
| Free cash flow margin | — | — | — | — | — | −4,866.7% | −4,553.8% | −679.7% | −322.4% | −32.1% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | −4,557.8% | 360.9% | −245.5% | 131.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | −3,292.4% | −230.8% | −123.8% | −149.6% | −348.4% | −91.3% |
| Return on assets | −6,154.0% | −12.6% | −1,004.7% | — | −515.5% | −156.7% | −96.3% | −113.4% | −182.9% | −44.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |